Migraine
Drug research and approvals for migraine: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 175 studies of migraine are recruiting on ClinicalTrials.gov, Health Canada has authorized 50 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 7 authorised medicines for it.
- Recruiting worldwide: 175
- Trials authorized in Canada: 50
- FDA orphan approvals: 0
- EU medicines: 7
- Laser Acupuncture for Chronic Migraine: Clinical Response, Traditional Chinese Medicine Syndrome Patterns, and Brain…NCT07891585 · Not applicable · Taichung Veterans General Hospital · starts Nov 1, 2026
- Acute Treatment of Vestibular Migraine by RimegepantNCT07871097 · Phase 4 · Wensheng Qu · starts Dec 1, 2025
- The Effect of Remote Electrical Neuromodulation (REN) on Conditioned Pain Modulation (CPM) in Migraine and FibromyalgiaNCT07841509 · Not applicable · Theranica · starts Jun 23, 2026
- A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigraineNCT07816367 · Phase 3 · TriGemX Bio, Inc. · starts Oct 2, 2026
- Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in AdultsNCT07792681 · Phase 2 / Phase 3 · Brise Pharmaceuticals Co., Ltd. · starts Sep 30, 2026
- High- vs Standard-Dose Intravenous Magnesium for Acute HeadacheNCT07779486 · Not applicable · University of Monastir · starts Jun 1, 2026
- Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in MigraineNCT07769255 · Not applicable · Beni-Suef University · starts Sep 1, 2026
- Headache Ear Auditory Dizziness Sinus (HEADS) RegistryNCT07754266 · Not reported · Association of Migraine Disorders · starts Jul 6, 2023
- A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic MigraineNCT07729462 · Phase 3 · Pfizer · starts Aug 26, 2026
How its trials ended
1,356 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 388 whose ending is known, 60% met their primary endpoint, 7% missed it and 32% stopped early.
- Completed, result not reported55741%
- Ongoing26520%
- Met its primary endpoint23417%
- Status unknown14611%
- Stopped: other or unclear725%
- Stopped: enrollment or feasibility302%
- Missed its primary endpoint282%
- Stopped: lack of efficacy111%
- Stopped: sponsor or business decision91%
- Stopped: funding3<1%
- Stopped: safety1<1%
| Aug 10, 2026 | A randomized, double-blind, placebo controlled study evaluating the efficacy and safety of EVO756 for the prevention of migraine in adultsEVO756 | Evommune | Ongoing |
| Jul 2, 2026 | Eptinezumab for the acute treatment of status migrainosus in the emergency department of a community hospital (ed-relief)Vyepti | Santé Québec- Centre Hospitalier De L’université De Montréal | Pending |
| Sep 10, 2025 | A multicentre, randomised, double-blind, placebo-controlled, dose escalation and dose finding phase II study to evaluate the safety and efficacy of IPN10200 in…IPN10200 | Ipsen | Ongoing |
| Aug 14, 2025 | Cannabis for the prophylactic treatment of migraine: a randomized double-blind placebo-controlled clinical trialCB-81 (cannabidiol-DELTA-9-tetrahydrocannabinol) | Governors of The University of Calgary | Ongoing |
| Jul 16, 2025 | A phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of xeomin®…Xeomin | Merz Therapeutics GmbH | Ongoing |
| Jul 16, 2025 | A phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of xeomin®…Xeomin | Merz Therapeutics GmbH | Ongoing |
| Mar 26, 2025 | An interventional efficacy and safety, phase 3, double-blind, parallel-group study to investigate intermittent prevention of menstrual migraine with rimegepant…Rimegepant (PF-07899801) | Pfizer | Ongoing |
| Mar 6, 2025 | A phase 3, multicenter, 12-week, double blind, placebo-controlled study to evaluate the safety and efficacy of atogepant for the preventive treatment of…Atogepant | AbbVie | Ongoing |
| Jul 23, 2024 | Eptinezumab as an adjunct to standard of care for migrane in an acute emergency context (migraine erase study)Vyepti | Fraser Health Authority | Ongoing |
| Oct 5, 2023 | An interventional, efficacy and safety, phase 3, double-blind, 3-arm, study to investigate pain response with intranasal (IN) zavegepant compared with placebo…Zavegepant (PF-07930207) | Pfizer | Closed |
| Mar 25, 2026 | (S)-N-(4-(2-(4-chlorophenyl)but-3-yn-2-yl)…Treatment of retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome | Drug Farm | Designated |
| Jul 20, 2016 | FlunarizineTreatment of hemiplegic migraine | Xenon Pharmaceuticals, Inc. | Designated |
| Aug 11, 2023 | AquiptaAtogepant | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
| Aug 17, 2022 | RayvowLasmiditan | Eli Lilly Nederland B.V. | EMA ↗ |
| Apr 25, 2022 | VyduraRimegepant | Pfizer Europe MA EEIG | EMA ↗ |
| Jan 24, 2022 | VyeptiEptinezumab | H. Lundbeck A/S | EMA ↗ |
| Mar 28, 2019 | AjovyFremanezumab | Teva GmbH | EMA ↗ |
| Nov 14, 2018 | EmgalityGalcanezumab | Eli Lilly Nederland B.V. | EMA ↗ |
| Jul 26, 2018 | AimovigErenumab | Novartis Europharm Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA